// App-Quantinova.ai

AB0299 : REAL-WORLD ASSESSMENT OF GP2015 (ETANERCEPT BIOSIMILAR, SDZ-ETN): AN INTERIM ANALYSIS OF DATA FROM THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE COMPACT STUDY

Researchers

Presenter

  • H. Kellner

Principal Investigators

  • A. Askari

  • T. Kupka

  • H. Friccius-Quecke

  • F. Furlan

  • S. Hachaichi

  • M. Schmalzing

Medical Centers

  • Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany

  • Robert Jones and Agnes Hunt Orthopedic Hospital NHS Foundation Trust, Department of Rheumatology, Oswestry, United Kingdom

  • Rheumazentrum Kupka, Altenburg, Germany

  • Sandoz/ Hexal AG, Holzkirchen, Germany

  • University Hospital Würzburg, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Etanercept biosimilar

  • GP2015

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved